This was confirmed by in vivo studies in APPswe/PS1dE9 mice, a common AD mouse model bearing mutant transgenes of the amyloid precursor protein and presenilin-1, which lead to an early-onset increase in parenchymal Aβ-levels and other clinically relevant AD-like symptoms [81]. This evidence concerns the gene APP and Alzheimer disease.